The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of personalized therapy guided by Exacta encyclopedic tumor analysis for women with broadly refractory advanced breast cancer.
 
Tim Crook
Stock and Other Ownership Interests - Datar Cancer Genetics
 
Sewanti Limaye
Employment - Sir H N Reliance Foundation Hospital and Research Centre
Leadership - Iylon; Sir H N Reliance Foundation Hospital and Research Centre
Stock and Other Ownership Interests - Iylon
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; Novartis; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; Novartis; Roche
 
Anantbhushan Ranade
Leadership - Avinash Cancer Clinic
 
Amit Dilip Bhatt
Leadership - Avinash Cancer Clinic
 
Sachin Apurwa
Employment - Datar Cancer Genetics
 
Darshana Patil
Employment - Datar Cancer Genetics
Leadership - Datar Cancer Genetics
Stock and Other Ownership Interests - Datar Cancer Genetics
 
Rajan Datar
Stock and Other Ownership Interests - Datar Cancer Genetics
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EOM Pharmaceuticals; Gaido; Iylon; LabCorp; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Prosperdtx; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation